ERBB2 and non-small cell lung carcinoma: Alterations of ERBB2 including gene amplification, protein overexpression, and missense mutations have been reported in multiple solid cancers, especially in breast cancer (4), stomach cancer (5), and non-small cell lung cancer (NSCLC) (6).